- Home
- GMAB vs TRMB Comparison
GMAB vs TRMB Comparison
Compare GMAB & TRMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TRMB
- Stock Information
- Founded
- GMAB 1999
- TRMB 1978
- Country
- GMAB Denmark
- TRMB United States
- Employees
- GMAB N/A
- TRMB N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TRMB Industrial Machinery/Components
- Sector
- GMAB Health Care
- TRMB Industrials
- Exchange
- GMAB Nasdaq
- TRMB Nasdaq
- Market Cap
- GMAB 17.4B
- TRMB 19.2B
- IPO Year
- GMAB N/A
- TRMB 1990
- Fundamental
- Price
- GMAB $29.01
- TRMB $79.99
- Analyst Decision
- GMAB Strong Buy
- TRMB Buy
- Analyst Count
- GMAB 6
- TRMB 7
- Target Price
- GMAB $40.40
- TRMB $93.86
- AVG Volume (30 Days)
- GMAB 2.6M
- TRMB 1.3M
- Earning Date
- GMAB 11-06-2025
- TRMB 11-05-2025
- Dividend Yield
- GMAB N/A
- TRMB N/A
- EPS Growth
- GMAB 132.41
- TRMB N/A
- EPS
- GMAB 25.10
- TRMB 1.47
- Revenue
- GMAB $3,845,670,022.00
- TRMB $3,600,900,000.00
- Revenue This Year
- GMAB $24.92
- TRMB N/A
- Revenue Next Year
- GMAB $15.97
- TRMB $6.93
- P/E Ratio
- GMAB $1.16
- TRMB $54.59
- Revenue Growth
- GMAB 29.57
- TRMB N/A
- 52 Week Low
- GMAB $17.24
- TRMB $52.91
- 52 Week High
- GMAB $33.65
- TRMB $87.50
- Technical
- Relative Strength Index (RSI)
- GMAB 46.20
- TRMB 51.66
- Support Level
- GMAB $28.08
- TRMB $77.83
- Resistance Level
- GMAB $29.35
- TRMB $81.50
- Average True Range (ATR)
- GMAB 0.65
- TRMB 2.10
- MACD
- GMAB -0.20
- TRMB 0.05
- Stochastic Oscillator
- GMAB 50.81
- TRMB 68.18
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About TRMB Trimble Inc.
Trimble Inc is a technology solutions provider that enables office and mobile professionals to connect their workflows and asset lifecycles to drive a more productive, sustainable future. The company has three reportable segments: Architects, Engineers, Construction, and Owners (AECO). This segment provides software solutions that sell through a direct channel to customers in the construction industry. Field Systems. This segment provides hardware and associated software solutions that sell through dealer partner channels. Transportation and Logistics (T&L). This segment provides solutions for customers working in long-haul trucking and freight shipping markets.